Get started
Iovance Biotherapeutics, Inc.Iovance Biotherapeutics, Inc.Iovance Biotherapeutics, Inc.

Iovance Biotherapeutics, Inc.

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Technicals Forecast Seasonals Options

IOVA chart


Full chart

IOVA upcoming earnings


Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪1.12 B‬ USD
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−1.30 USD
Net income (FY)
‪−372.18 M‬ USD
Revenue (FY)
‪164.07 M‬ USD
Shares float
‪265.54 M‬
Beta (1Y)
1.65

Employees


Employees (FY)
838
Change (1Y)
+281 +50.45%
Revenue / Employee (1Y)
‪195.79 K‬ USD
Net income / Employee (1Y)
‪−444.13 K‬ USD

About Iovance Biotherapeutics, Inc.


Sector
Health Technology
Industry
Biotechnology
CEO
Frederick G. Vogt
Website
iovance.com
Headquarters
San Carlos
Founded
2007
FIGI
BBG000FTLBV7
Iovance Biotherapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of cell therapies as novel cancer immunotherapy products. Its lead product candidate, LN-144 for metastatic melanoma, is an autologous adoptive cell therapy utilizing tumor-infiltrating lymphocytes (TIL), which are T cells derived from patients' tumors. The company was founded by Robert T. Brooke on September 17, 2007 and is headquartered in San Carlos, CA.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—

IOVA news



Ideas



See all ideas 

Technicals


Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

Check out other big names from the same industry as IOVA.

Frequently Asked Questions


The current price of IOVA is 3.23 USD — it has increased by 3.33% in the past 24 hours. Watch Iovance Biotherapeutics, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Iovance Biotherapeutics, Inc. stocks are traded under the ticker IOVA.
IOVA stock has risen by 21.35% compared to the previous week, the month change is a −3.67% fall, over the last year Iovance Biotherapeutics, Inc. has showed a −73.85% decrease.
We've gathered analysts' opinions on Iovance Biotherapeutics, Inc. future price: according to them, IOVA price has a max estimate of 32.00 USD and a min estimate of 5.00 USD. Watch IOVA chart and read a more detailed Iovance Biotherapeutics, Inc. stock forecast: see what analysts think of Iovance Biotherapeutics, Inc. and suggest that you do with its stocks.
IOVA reached its all-time high on Jun 7, 2011 with the price of 165.00 USD, and its all-time low was 1.01 USD and was reached on May 3, 2013. View more price dynamics on IOVA chart.
See other stocks reaching their highest and lowest prices.
IOVA stock is 9.12% volatile and has beta coefficient of 1.65. Track Iovance Biotherapeutics, Inc. stock price on the chart and check out the list of the most volatile stocks — is Iovance Biotherapeutics, Inc. there?
Today Iovance Biotherapeutics, Inc. has the market capitalization of ‪1.06 B‬, it has increased by 0.62% over the last week.
Yes, you can track Iovance Biotherapeutics, Inc. financials in yearly and quarterly reports right on TradingView.
Iovance Biotherapeutics, Inc. is going to release the next earnings report on May 13, 2025. Keep track of upcoming events with our Earnings Calendar.
IOVA earnings for the last quarter are −0.26 USD per share, whereas the estimation was −0.27 USD resulting in a 2.88% surprise. The estimated earnings for the next quarter are −0.24 USD per share. See more details about Iovance Biotherapeutics, Inc. earnings.
Iovance Biotherapeutics, Inc. revenue for the last quarter amounts to ‪73.69 M‬ USD, despite the estimated figure of ‪72.11 M‬ USD. In the next quarter, revenue is expected to reach ‪81.53 M‬ USD.
IOVA net income for the last quarter is ‪−78.56 M‬ USD, while the quarter before that showed ‪−83.54 M‬ USD of net income which accounts for 5.96% change. Track more Iovance Biotherapeutics, Inc. financial stats to get the full picture.
No, IOVA doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Apr 16, 2025, the company has 838 employees. See our rating of the largest employees — is Iovance Biotherapeutics, Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Iovance Biotherapeutics, Inc. EBITDA is ‪−351.67 M‬ USD, and current EBITDA margin is −214.34%. See more stats in Iovance Biotherapeutics, Inc. financial statements.
Like other stocks, IOVA shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Iovance Biotherapeutics, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Iovance Biotherapeutics, Inc. technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Iovance Biotherapeutics, Inc. stock shows the sell signal. See more of Iovance Biotherapeutics, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.